Long-Term Effects of Ozempic This article was reviewed by Lynn Marie Morski, MD, JD. You may have heard about — or maybe even ...

Credit: Novo Nordisk. If the products were acquired through the Novo Nordisk Patient Assistance Program, the product is genuine and not counterfeit. Products with the “EXP/LOT” text written on the ...

Novo Nordisk announced today that Health Canada has approved Ozempic® (semaglutide injection) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction ...

This article was reviewed by Darragh O’Carroll, MD. Key takeaways: Semaglutide nausea is common: About 20 percent of Ozempic® patients and 44 percent of those on … ...

Hims & Hers said that existing patients will have the opportunity to transition to FDA-approved medicines when their providers deem it clinically appropriate. ・The company stated that Ozempic ...

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the year in 2025. Ozempic isn’t the only drug that mimics the natural GLP-1 ...

The generic versions of semaglutide are expected to be at least 50% cheaper— ₹5,000 for a weekly dose—than Ozempic in India .

New research suggests that drugs like Ozempic and Wegovy might trigger more than just a slimmer waistline. Many users have reported digestive issues while taking the medications, including nausea, ...

Novo Nordisk (NYSE:NVO)and US telehealth company Hims & Hers (NYSE:HIMS) have announced a collaboration that will bring the Danish drugmaker’s weight-loss medications Wegovy and Ozempic to Hims & Hers ...

The Bermuda Health Council is investigating Allshores’ exclusive pharmacy deal while parties to that deal are breaching the council’s formulary. If it cannot, or chooses not to, enforce its own ...

Hims & Hers shares surged 46% after partnering with Novo Nordisk to offer FDA-approved Ozempic and Wegovy, moving away from ...

Ozempic (R) was approved by Health Canada in 2018. Ozempic (R) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control.